Current treatment methods for patients with triple-negative breast cancer (TNBC) are very limited, and the prognosis of TNBC is relatively poor. It has been reported that glucose transporter 1 (GLUT1) is overexpressed in breast cancer cells; however, its association with the prognosis is mostly unclear. Moreover, retinoblastoma gene 1 (RB1) might be used as a biomarker for the sensitivity of breast cancer cells to GLUT1 inhibitors, which brought us to the hypothesis that there might be a close correlation between the expression of GLUT1–4 and the expression of RB1. In this study, we systematically analyzed the co-expression of GLUT1–4 and the influence of GLUT1–4 gene expression on the prognosis of breast cancer using data mining methods. We also explored possible relationships between GLUT1–4 and RB1 expression in breast cancer tissues. We used public databases such as ONCOMINE, GEPIA, LinkedOmics, and COEXPEDIA. According to the results, the mRNA expression of SLC2A1 was significantly higher in breast cancer, while the expression levels of SLC2A2–4 were downregulated. The results also indicate that GLUT1 expression does not have significant influence on the overall survival of patients with breast cancer. The mRNA expression of SLC2A1 and RB1 is significantly correlated, which means that tissues with high RB1 mRNA expression might have relatively higher mRNA expression of SLC2A1; however, further study analyzing their roles in the expression regulation pathways with human samples is needed to verify the hypothesis. The mRNA expression of SLC2A1 was significantly higher in breast cancer. The overall survival of breast cancer patients wasn’t significantly correlated with GLUT1–4 expression. The mRNA expression of SLC2A1 and RB1 is significantly correlated according to the analysis conducted in LinkedOmics. It provides reference for future possible individualized treatment of TNBC using GLUT1 inhibitors, especially in patients with higher mRNA expression of RB1. Further study analyzing the roles of these two genes in the regulation pathways is needed.

中文翻译：

---

乳腺癌中 GLUT1-4 和 RB1 的共表达及预后分析

目前三阴性乳腺癌（TNBC）患者的治疗方法非常有限，且TNBC的预后也相对较差。据报道，葡萄糖转运蛋白1（GLUT1）在乳腺癌细胞中过度表达；然而，其与预后的关系大多尚不清楚。此外，视网膜母细胞瘤基因1（RB1）可能被用作乳腺癌细胞对GLUT1抑制剂敏感性的生物标志物，这使我们得出这样的假设：GLUT1-4的表达与RB1的表达之间可能存在密切相关性。 。本研究采用数据挖掘方法系统分析了GLUT1-4的共表达情况以及GLUT1-4基因表达对乳腺癌预后的影响。我们还探讨了乳腺癌组织中 GLUT1-4 和 RB1 表达之间的可能关系。我们使用 ONCOMINE、GEPIA、LinkedOmics 和 COEXPEDIA 等公共数据库。结果显示，乳腺癌中SLC2A1的mRNA表达显着升高，而SLC2A2-4的表达水平下调。结果还表明GLUT1表达对乳腺癌患者的总生存期没有显着影响。SLC2A1与RB1 mRNA表达量显着相关，即RB1 mRNA表达量高的组织中SLC2A1 mRNA表达量可能相对较高；然而，需要进一步研究分析它们在人类样本表达调控途径中的作用来验证这一假设。SLC2A1 mRNA 表达在乳腺癌中显着升高。乳腺癌患者的总生存率与 GLUT1-4 表达没有显着相关。根据 LinkedOmics 的分析，SLC2A1 和 RB1 的 mRNA 表达显着相关。为未来可能使用GLUT1抑制剂个体化治疗TNBC，尤其是RB1 mRNA表达较高的患者提供参考。需要进一步研究分析这两个基因在调控途径中的作用。